key: cord-0883945-u2a19216
authors: Das, Ankur; Ahmed, Raja; Akhtar, Suraiya; Begum, Khaleda; Banu, Sofia
title: An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies
date: 2021-04-01
journal: Gene Rep
DOI: 10.1016/j.genrep.2021.101122
sha: 129ed8b652585b3c671dae5a636a88431a00c25f
doc_id: 883945
cord_uid: u2a19216

Coronavirus Disease 2019 (COVID-19) manifests as extreme acute respiratory conditions caused by a novel beta coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which is reported to be the seventh coronavirus to infect humans. Like other SARS-CoVs it has a large positive-stranded RNA genome. But, specific furin site in the spike protein, mutation prone and phylogenetically mess open reading frame1ab (Orf1ab) separates SARS-CoV-2 from other RNA viruses. Since the outbreak (February - March 2020), researchers, scientists, and medical professionals are inspecting all possible facts from every possible aspect including its replication, detection, and prevention strategies. This led to the prompt identification of its basic biology, genome characterization, structural and expression based functional information of proteins, and utilization of this information in optimizing strategies to prevent its spread. This review summarizes the recent updates on the basic molecular biology of SARS-CoV-2 and prevention strategies undertaken worldwide to tackle COVID-19. This recent information can be implemented for the development and designing of therapeutics against SARS-CoV-2.

reason of animal to human transmission [40] . Recently, the full-length structure of S-protein have been revealed, but as a mixture of pre-fusion and post-fusion forms [41] . Additionally, cryo-ET in combination with molecular dynamics was utilized to trace the rearrangement and conformational change at molecular level of S protein from pre to post fusion [42] . Thus, opens up opportunities to explore structure-based drugs which targets during viral fusion to human cell membrane. Interestingly, a group of scientists recovered a mutant strain (Del-mut-1, 10 amino acid) in S1/S2 junction from Vero-E6 cells which did not show any major change in lung pathology and hence could be a lead for attenuated vaccines [43] . Also, protease inhibitor targeting the furin and TMPRSS2 activity have shown positive results in inhibiting SARS-CoV-2 and may be promising in the therapeutics field [44, 45] 

The viral genome entry into the host cytoplasm is facilitated by S protein, which is the translation product of 1273 amino acids encoded by S gene. It mediates the fusion of envelope with the host's cell membrane [46] . The product encoded by Orf1a is polyprotein 1a (pp1a, 4405 amino acid residue). Addition of 1b encoded sequence to 1a, yield 7096 amino acid residue protein (pp1ab) which occurs as a result of ribosomal shifting of -1 reading frame [47] . Thus, Orf1ab encodes a huge replicase polyprotein. The four structural genes S, E, M, and N encodes the Spike protein (1273 amino acid), Envelope protein (75 amino acid), Membrane protein (222 amino acid), and Nucleocapsid phosphoprotein (419 amino acid) respectively. These four structural proteins in SARS-CoV-2 have been identified and characterized, where Envelope (E) and Membrane (M) protein are found to be involved in virus packing, and spike glycoprotein (S) in viral entry [48, 49, 25 ]. The Nucleocapsid (N) protein is involved in RNA binding and packaging [25] . Except spike protein, very limited structural information on the other structural proteins are available yet. N protein in SARS-CoV-2 is believed to play role during genome replication [50] . An identical leader sequence (protein of 180 amino acids) is carried by each mRNA [23, 36, 37] . Orfs of SARS-CoV-2 have been validated and structural information of 9 accessory proteins have been discussed till date [25, 21, 47] (Fig 2A) . SARS-CoV-2 encodes Orf10 in the genome terminal which was absent in SARS-CoVs and related strains, and a single Orf8 is found instead of Orf8a and Orf8b [51] . The cryo-EM structure of Orf3a revealed a unique fold structure harboring a channel which is joined to the cytoplasm [52] . Not much information of Orf7a and Orf9b in SARS-CoV-2 is available yet, but they are believed to play a similar role as in SARS-CoV [53, 54] . SARS-CoV-2 Orf8 was resolved based on homology model to Orf7a, and it was found to interfere with major histocompatibility complex-1 (MHC-1) and inhibit presentation to the immune cells and interferon signaling in the host cell [55, 56] . Similarly, Orf3b and Orf6 are also reported to be involved in downregulation of Interferon (IFN-1) signaling [57, 58] . Thus, interfering with the human immune system. A recent study suggested the internal modification sites concerning the poly (A) tail of the transcript of Orf1ab and S which are predicted to play a crucial role in RNA stability inside the host [59] . Due to the complex regulation of viral RNA synthesis and quick recombination, SARS-CoV-2 may show flexibility in specificity and sensitivity.

varied enzymatic activities. The nsps undergo post-translational changes and regulate the activities of the replicative proteins [32] . Orf1a produces pp1a (440-500 kDa) which gets processed into 11nsps and ribosomal frameshift results in the continuation of translation of Orf1b producing a huge polypeptide pp1ab (740-810 kDa) which gets processed into 16 nsps [59] (Fig. 2C) . The 16 nsps encoded by Orf1ab are directly involved in the infection cycle inside the host [28] . A study reported an extra N-terminal hairpin motif in SARS-CoV-2 nsp12, which was absent in earlier SARS-CoV [61] . Earlier coronaviruses including SARS-CoV possess a papain-like protease for the processing of polyproteins [62] . But a genome-wide structure and functional modeling by Zhang lab, University of Michigan revealed an additional 3C-like protease (3CL-PRO) in SARS-CoV-2, which may be responsible for cleaving the C-terminus of replicase polyprotein and recognizes substrate containing sequence ILMVF-Q-I-SGACNN and also can bind an ADP-ribose-1-phosphate [63] . Nsp1structure in complex with ribosomes was revealed in SARS-CoV-2, and reported to play a significant role during infection [64, 65] . Not much information is yet known about SARS-CoV-2 nsp2, however it is believed that, it may contribute to the infectivity of the virus [66] . Determination of the structure of papain-like protease (deposited in PDB), have revealed a homotrimeric fold, which is also found to be conserved in SARS-CoV and MERS CoV and is clearly involved in cleavage activity [67] . The structural similarity of SARS-CoV-2 papain-like protease to SARS-CoV-2 have led researchers to explore drug development and several inhibitors [67, 68] . Huang and his team also demonstrated de novo designing of peptide that blocks the interaction between SARS-CoV-2 spike and human ACE2 [69] . Structurally, nsp3 harbors two ubiquitin-like domain, where domain 1 may interact with ssRNA and N protein [70] . However, the role of nsp3 domain 2 is still unclear in SARS-CoV-2. The nsp5 together with the papain-like protease forms the main protease that is reported to be involved in Orf1ab cleavage [29] . Replication and transcription of the viral genomic RNA is carried out mainly by nsp12 possessing RNA-dependent RNA polymerase (RdRp) activity [71] . The cryo-EM structure of the complex nsp12-nsp7-nsp8 at 2.9-A˚ and N terminal beta-hairpin domain have been resolved [72] . The complete structure, almost all residues is revealed, where residues 4 to 28 and 51 to 249 include 8 helices and 5-stranded beta-sheet respectively towards the N terminus. The three conserved structure of the polymerase viz. finger domain (L366-A581), palm domain (T582-P620 and T680-Q815), and a thumb domain (H816-E920) are also shown where palm domain forms the active site of the enzyme [61]. Recently, it has been found that substitution of amino acids in nsp7-8-12 peptide of SARS-CoV-2 have resulted in the decrease activity of RdRp and stability of the proteins [73] . Hence, RdRp remains a potent candidate for drug target [74] . The information revealed regarding the structural rearrangement of nsp7-nsp8 and its association with the regulatory role and activity of the polymerase could be utilized towards designing targets for future therapeutics [75] . SARS-CoV nsp13 helicase is considered to be a multi-functional protein harboring a zing-binding domain in N-terminus showing RNA and DNA duplex-unwinding activities (5ˊ-3ˊ) [76] . The structure of SARS-CoV-2 nsp13 helicase coupled with the core RdRp has been revealed and interaction was detected with nsp7-8-12 [77] . The structure of nsp10-16 complex has been determined in SARS-CoV-2 and found to be highly similar to SARS-CoV and MERS CoV [78] . The structure of nsp14 however in SARS-CoV-2 has not yet been resolved. The proof-reading activity of nsp13-RdRp complex was suggested initially in SARS-CoV-2 [77] , despite the structural analysis of the complex, its physiological role still remains unknown. Nsp15 is uridylate-specific Endoribonuclease (NendoU) harbor uridylate specific enzyme in the presence of Mn 2+ , 2ˊ-O-methylase is predicted to mediate mRNA cap 2ˊ-O-ribose methylation to the 5ˊ-cap of viral mRNA [63] . SARS-CoV-2 nsp15 is found to be conserved in SARS-CoV and MERS CoV [79, 80] . Nsp9 in SARS-CoV-2 is shown to be in dimeric form [81] , and in other CoVs it was found to be involved in viral replication [82] . A recent study reported the structure of nsp10-16 complex and its structural similarity to SARS-CoV and MERS CoV, indicating its probable conserved function [78] . Nsp10 can additionally interact with nsp14 to aids the exonuclease activity. Moreover, nsp10 is known to have multiple function during RNA capping [83] . SARS-CoV-2 ExoN has been predicted to be involved in repair mechanisms [71] .

The entry process of 2019 coronavirus (SARS-CoV-2) follows the usual pattern of a common virus life cycle. The spike protein with the host ACE2 receptor. The cellular Human Airway-Trypsin like protease (HAT), cathepsins, and Transmembrane protease serine 2 (TMPRSS2) breaks the Sprotein and facilitate the fusion of cellular and viral membrane and release of SARS-CoV-2 genetic material RNA inside the host cell takes place [84, 85, 31] . Apart from TMPRSS2, few others genes including BSG were recently studied for genetic variation in 131 COVID-19 positive patients and showed that host genes variation may be associated with severity and susceptibility of infection. [86] . The receptor-binding region (RBD) of SARS-CoV-2 uses the hACE2 receptor as an entry key [26] . The replicase gene of the genomic RNA of the virions, once inside the host cell cytoplasm, is translated using host cell machinery. After the formation of nsp by proteolytic cleavage, some of the nsp combine with the sense strand (RNA+) to form the replicase transcriptase complex which facilitates RNA replication. When RNA+ strand is replicated, it produces genomic RNA but that happens to be antisense RNA (RNA-). The antisense RNA strand can be replicated back into the genomic (RNA+) strand or can be transcribed into sub-genomic RNAs by discontinuous transcription [87] . The sub-genomic RNAs are mRNAs that can be translated into viral structural proteins. Many different structures have been proposed which regulate alternate RNA synthesis stages which including seven stem-loop structures at the 5'-UTR [88, 89, 90, 91] ; a bulged stem-loop, a pseudoknot, and a hypervariable region at the 3'-UTR [92, 93, 94, 95] . CoVs genomic RNA replication is mediated by RNA-directed RNA polymerase (Pol/RdRp) which is also responsible for transcription of the viral RNA genome. There is experimental evidence for SARS-CoV that nsp7 and nsp8 activate and confer processivity to the RNA-synthesizing activity of the polymerase [85] . The synthesis of sub-genomic RNA through the discontinuous extension of the antisense RNA strand is mediated by the fusion of leader transcription regulating sequences (TRS) and body TRS. It has been found that Pol/RdRp when reaches at any one of the body TRS, it pauses and then either continues elongation to the next TRS or jumps to the leader TRS, thus terminating transcription [26] . Following the formation of sub-genomic and genomic RNAs, the viral structural proteins encoded by the subgenomic RNAs are translated. These proteins are then trafficked to the Endoplasmic Reticulum followed by the entry into the Golgi Intermediate Compartment via the secretory pathway. The viral genomes are encapsulated by the N-protein into the membranes of the ER-Golgi intermediate compartment (ERGIC) where both the structural proteins and viral genome form mature virus particles [96, 97] . Both the M and E proteins function together to form the coronavirus envelops [97] . Finally, the mature virions transported via vesicles and released out of the cell through exocytosis. While the virus completes its life cycle in the host cell, the signaling molecules of the host immune system already starts its action either by regulating the expression of the genes associated with immune response or by initiating cascade of reactions necessary for immune response. SARS-CoV-2 affect CD4 + and CD8 + T cells of the host resulting in a smaller number of IFN production [98] . In humans, after cell infection, the up-regulation of Interferon stimulated genes (ISGs) is necessary for the induction of Interferons for antiviral defense [99] . The binding of the transcription factor signal transducer and activator of transcription factor 1 (STAT1) homodimers to ISGs are moderated by the various IFNs (IFNa, IFNb, IFNg, and IFNl) and thus, play a crucial role in host defense (signaling the nearby cells) [100, 101] . Recently, it has been suggested that uses of approved IFN in clinical therapy against SARS-CoV-2 may either vanish or worsen the symptoms of COVID-19 [102, J o u r n a l P r e -p r o o f 103] . A recent finding suggested that mutation in the type I IFN and related genes may be associated with severe pneumonia [104] . Therefore, administration of type I IFN specially in the early stage of SARS-CoV-2 infection in patients may lessen the effect of life-threatening pneumonia. Experimentally it has also been shown that IFNa drives the up-regulation of ISGs in ACE2 expressing cells and high expression of the same in influenza-infected upper epithelial cells [105] . Thus, this information can be considered for designing IFN-system targeted therapeutics. It is clear that upon an attack of coronaviruses, due to the huge activation of immune molecules in the host cell, a cytokine storm is generated which results in adverse damage of both targeted and nearby tissues (Fig. 3) [16, 106] . A study suggested that interleukin 6 (IL-6) which is generated by leukocytes plays a leading role in inducing the storm [16] . Moreover, IL6 is known to be associated with inflammatory response, disease, disorders, differentiation of B lymphocytes, cell growth regulation, and more importantly with cytokine release syndrome (CRS) [12, 106] . People with diabetes, heart disease, pulmonary disease, and kidney problem when infected with SARS-CoV-2 have shown worse outcomes because of the plasmin and proteases which tend to break the S protein (furin site) which eventually increases its virulence [107] . However, this system could be a target for future therapeutics.

The shortage of first-hand testing kits and the unavailability of reliable and efficient diagnostic tools also elevated the risk of spreading COVID-19 infection. So far, several diagnostic tools were developed to manage the COVID-19 outbreak. Information at the molecular level and the use of molecular biology tools have always been promising in detecting viral diseases [108] . Techniques adopted till date around the world for diagnosis and controls of COVID-19 are summarized:

Molecular biology-based diagnostic tools require information regarding the genomic and transcriptomics of the target organism. Comprehending molecular biology not only help in the detection of such pathogens, but also opens the way to target and combat the same. One such technique is Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) [109] which has been used since long in the detection of pathogenic viruses involving in respiratory infection [110, 111, 112] . Scientists from different regions adopted various assays of RT-PCR approved by WHO, CDC, and FDA EUA [113, 114, 115, 116] . However, the availability of RT-PCR tools and reagent kits are not up to the demand. Additionally, many reports suggests that though RT-PCR is known for its broad sensitivity (can detect even at low viral load) [117] , but in clinical practice, the diagnostic sensitivity is 50-70% [118, 119, 120] as false negative results are often being obtained for a single test [121, 122] . The false negative results may be due to several factors, viz. errors in sample preparation, machine handling, errors in correct interpretation of the results. Moreover, RT-PCR is known for its high specificity (about 99%) [123, 124] , hence, contamination with trace amount of SARS-CoV-2 nucleic acids in the sample may result in false positivity [125] . Thereby, proper protocol standardization to minimize contamination, optimization and validation is required for increment of accuracy in diagnosis. In addition, viral evolution and time of SARS-CoV-2 test performed (i.e., time of course of infection at which the sample is obtained) are important factors in RT-PCR sensitivity [126, 127] . Isothermal amplification techniques viz. recombinase polymerase amplification [128] , loop-mediated isothermal amplification (LAMP) [129] , Reverse Transcriptase LAMP (RT-LAMP) [130, 131] , helicase dependent amplification [132] are in the developmental and clinical stage for SARS-CoV-2 detection. X-ray and chest CT scan insights better screening and diagnosis and simultaneously lowers the risk of spreading the disease [133, 134] . Artificial Intelligence techniques can be coupled with a Chest CT scan for safe, efficient, and accurate image acquisition, segmentation, and diagnosis of COVID-19 [135] . RNA sensing is possible due to CRISPR-Cas technology that utilizes Cas12 coupled with isothermal amplification and DETECTOR technique, [136] and Cas13a/C2c2 proteins [137] following Cas13 based detection methodology and SHERLOCK detection protocol [138] .

One of the common types of rapid diagnosis of COVID-19 is detection of antigens and antibodies (in the blood samples of the individuals that have likely been infected by SARS-CoV-2) [139] . However, antibodies produced against SARS-CoV-2 may counteract with other pathogens resulting in falsepositive detection. Also, several factors such as the severity of the disease, age of the infected individual, and medication may result in hindrance in the actual diagnosis of COVID-19 infection [140] . Similarly, rapid diagnostics using antigens (viral protein) may not provide full-proof diagnostics which may be due to limitations in quality and time of sample collection, concentration of target antigen in the sample, and so forth. In a note of this, uses of antibodies and viral proteins for rapid diagnosis of COVID-19 have not been yet approved by WHO although encouraged scientists and researchers to utilize it in disease surveillance and epidemiologic research [141, 142] . Very recently, first indigenous antibody detection kit (human IgG ELISA test kit) was developed by National Institute of Virology (NIV), Pune which will aid in the surveillance of SARS-CoV-2 infected population, [143] .

Diagnosis at the preliminary level is at most important to estimate as well as minimize the spread of the virus from an infected person to a healthy individual. Though RT-PCR based diagnosis is more accurate, its time-consuming property leads to the need for non-laboratory rapid testing kits. Several pharmaceutical industries and companies have come up with rapid antibody (IgM/IgG) testing kit and Real-time PCR mediated SARS-CoV-2 diagnostic kits. US-FDA and CE have approved several realtime PCR kits and CE marked a rapid antibody test for SARS-CoV-2 diagnosis and can be used directly after due marketing approval from DCGI. CSIR India has come up with low-cost paper-strip test kits that use a cutting-edge-gene-editing tool (CRISPR-Cas9) to target and identify the genome sequences of the novel coronavirus in the samples of suspected individuals within an hour [144] . As of 1st May 2020, 45 real-time PCR kits (10 are Indian based company) and 23 antibody-based rapid tests (9 from Indian based company) have been validated by ICMR and NIV Pune respectively [145, 146].

Research is at its peak to develop an efficient and effective solution considering molecular biology and the genetic makeup of both the virus and host system. Based on approaches undertaken by different countries around the globe, the strategies have been summarized into Western, Homeopathy, and traditional. Certain innovative ways undertaken to prevent the disease from spreading are also summarized. Research and trials are ongoing for approximately 86 vaccines are in the phase of clinical trial and 12 vaccines are approved for emergency around the world [147, 148] . The first human trial for COVID-19 vaccine mRNA-1273 was done by the USA that was developed by the National Institute of Allergy and Infectious Disease (NIAID) scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge [149] . Following that, a series of trials have been carried out considering both host and viral proteins targeting mainly the replication process. [150] . The first vaccine mRNA-1273 was designed to target specifically the spike protein to prevent binding with the host receptor ACE2 (Angiotensin-converting enzyme 2) [151, 152] . On the other hand, researchers have also focused on the use of Hydroxychloroquine and Azithromycin, since it raises the pH of the cell leading to decreased enzymatic activity and viral replication. It was also found to resists the effective binding of Spike-ACE2 [153, 154, 155, 156] . Chloroquine and Zinc have similar functions to Hydroxychloroquine and Azithromycin, but Chloroquine serves as a gateway for zinc to diffuse through the cell [153, 154, 157, 158] . Ramdesivir (GS-5734), an inhibitor to RNA-dependent RNA polymerase showed promising results against SARS-CoV-2 in vitro. As a result, the Food and Drug Administration approved Ramdesivir for use against SARS-CoV-2 in adult and paediatric patients aged 12 years and weighing at least 40 kilograms [159] . Additionally, Argentina's scientists discovered that high doses of dexamethasone are effective in treating Acute Respiratory Distress Syndrome caused by SARS-CoV-2 [160] .

Moreover, certain companies namely, Moderna, Pfizer-BioNTech, Zydus, Urivac, etc. are working on a vaccine based on genetic approach of passive immunization [147] . [147] . Besides the companies and institutes mentioned above, Several Institutes such as Murdoch Children's Research Institute, Washington University, India's National Institute for Research in Tuberculosis, The Serum Institute of India, etc. are working on repurposed vaccines; i.e. vaccines which are already in use to treat other diseases with similar symptoms to COVID-19 [147] . Several Pharmaceutical industries also considered drugs namely Arbidol Hydrochloride, Ivermectin, Fingolimod, Methylprednisolone, and Ritonavir [161, 156] . Several antibodies have also been raised that inhibit or neutralize the virus. Scientist from Netherlands and Germany discovered human monoclonal antibody 47D11, which target a conserved epitope of the S1 B RBD domain [162] . B 38 is another monoclonal antibody that can block SARS-CoV-2 from binding to the ACE2 receptor [163] . Israel Institute of Biological Science is associated with the development of a monoclonal antibody and a VSV-ΔG-spike vaccine [164, 165] . (List of vaccines under clinical trial developed by different Pharmaceutical Company is depicted in Table 1 ). Council of Scientific and Industrial Research (India) has received approval for the clinical trial of two drugs -Favipiravir and Phytopharmaceutical by the Drug Control General of India (DGCI) to combat coronavirus [184] . A group of scientists of Israel also discover antibodies (REGN10933, REGN10934, REGN10987, REGN10989) which together can act against the spike protein [185] .

J o u r n a l P r e -p r o o f Homeopathic medicines are being considered for the treatment of COVID-19 in a few countries, including many Indian states. Arsenic album is regarded as an immune booster by Central Council for Research in Homoeopathy [186] . The world-first clinical trial of Homeopathic medicine Bryonia alba 200 for the treatment of COVID-19 has begun at Neminath Homeopathic Medical College, Agra (India). During the initial trial, Bryonia Alba-200 was regularly provided to 42 patients, and within 5-7 days, the test results were found to be negative for 40 patients. Further studies for its effectiveness are still in progress [186, 187] . Cuba, a North American country also declared about the distribution of Prevengovir, a new homeopathic immunological booster [188] . In Hong Kong, a study was performed with 18 COVID-19 patients who had a variety of symptoms. Patients treated with Bryonia Alba 30C recovered 20% in the first 12 hours and 70-95 percent on day 3, patients treated with Gelsemium sempervirens 30C recovered 20-50 percent in the first 12 hours and 70-100 percent on day 3, patients treated with Arsenicum album 30C recovered 50% in the first 12 hours and 100% on day 3, and patients treated with Eupatoriu 30C recovered 50% in the first 12 hours and 100% on day 3. [189] . In Italy, 50 patients were treated with medicines namely Arsenicum Album, Phosphorus Flavus, Atropa Belladonna, Antimonium Tartaricum, Eupatorium Perfoliatum, Hepar Sulphur, Lycopodium Clavatum, Kalium Phosphoricum which showed overall recovery and no patients were needed to be hospitalized during the recovery period [190] . Despite the fact that many homoeopathic medicines showed promising results in COVID-19 patients, this branch of medicine is understudied in terms of efficacy and needs further research.

Traditional medicine was successfully used in China for treatment of approximately 58.3% of the cases [176, 177] . Shanghai Institute of Materia Medica and Wuhan Institute of Virology found Shuanghuanglian to be promising in inhibiting SARS-CoV-2 3CL protease and the replication of SARS-CoV-2 in Vero E6 cells. Baicalin and baicalein, two known compounds present in Shuanghuanglian showed inhibitory effect against the protease [155, 156, 191] . Moreover, Lianhuaqingwen capsule, which is known for its anti-inflammatory activity and a regulator of immune responses to clear viral load. A clinical trial was started to study its efficiency against SARS-CoV-2 which is currently in Phase-3 [192, 193] . Yupingfeng San, a cocktail of three herbs namely Astragalus, Fangfeng, and Atractylodes was found to improve immune responses [191] . Sangjuyin and Yinqiao san are other two Chinese traditional medicines that are reported to be used in lung heat clearance and cough relief [191] . Qingfei paidu decoction shows an efficiency of 90% against COVID-19 symptoms. It was found to enhance immune responses and inhibit duplication of the SARS-CoV-2 genome by blocking ribosomal proteins [194] . A group of Scientist further mentioned few Chinese traditional remedies which include Qingfei Paidu Tang, Xiang Sha Liu Junzi Tang, Shen Ling Baizhu San, Qingfei Paidu Tang, Qingwen Baidu Yin, Shen Fu Tang, Ma Xing Shi Gan Tang, Da Yuan Yin, Xia Ling Tang which are used in China to deal with COVID-19 but their efficiency against the virus still awaits detailed study [195, 196] . India also had a great treasure of traditional knowledge in medical science, well-known as Ayurveda. In Chennai, a patient treated with Sudarsana Churna, Talisadi Churna with honey, and Dhanwantara Gutika was observed to recover on 16 th day and tested negative on 33 th day [197] . [198, 199] . Recently, Thailand Health Ministry have approved Andrographis paniculata for the treatment of COVID-19 patients [200] . (Status of the natural products that have been J o u r n a l P r e -p r o o f considered for clinical trial against SARS-CoV-2 is described in Table 1 ) This branch of science is also relatively less investigated towards effectiveness to COVID-19 and demands a detailed and thorough study.

Dealing with the COVID-19 outbreak is of high concern and from the initial stage of the onset of these pandemic, researchers, high-tech manufacturers, designers came forward with innovative equipment for the prevention of the SARS-CoV-2 virus. PPEs like masks, gloves, and other essentials like rapid testing facilities, ventilators are needed in extraordinary quantities especially for the frontline coronavirus warriors. Chinese company based Anti-virus snood, smart helmet, 3D printed isolation wards, drones; Italian company based 3D printed ventilator valves; South Korean based coronavirus booth; Czech based 3D printed face shield [209] ; Indian company based cost-effective novel mask [210] , bag valve mask ventilator (Ambu bag) by Mahindra and Mahindra Company, DRDO based UV disinfection tower [211] , mobile virology research lab and diagnostic laboratory (MMVR) [212] , portable or fixed microwave sterilizer -ATULYA [213] , IIT based incubation boxes [214] to name a few are being designed for prevention and surveillance of COVID-19 outbreak.

In a sea of different platforms for the possible treatment of COVID-19, CRISPR-Cas mediated gene-editing technology remains promising which can be used to manipulate target genes using guide RNA and Cas protein (cleavage protein) [215, 216, 217] . Gene knockout was successfully employed in coronaviruses using CRISPR technology [218, 219] . With advances in detection and identification of more Cas13 target sites in human infectious coronaviruses, CRISPR-Cas13 can be programmed with updated RNA sequences [220] . Delivery of CRISPER-Cas into the target RNA in a living individual could be using lipid nanoparticles [221] , HEDGES platform [222] , or ribonucleoprotein complex [223] but is still challenging. The Cas13d can be harnessed to target a wide range of ssRNA viruses including SARS-CoV-2 along with CARVER (Cas13-assisted restriction of viral expression and readout) for rapid diagnostics and anti-viral drug development [221] . Besides this molecular platform, nanotechnology-based (silver and gold-based) therapy [224, 225, 226, 227, 228] , ultrashort pulsed laser irradiation technology using short-lived reactive oxygen species (singlet oxygen) [229, 230] , and ultrasound-based therapy [231] could be employed in the medicament of COVID-19. Although these emerging techniques are under development, extensive research, and laboratory diagnosis with proper validation are prerequisite to bringing into play in combating COVID-19. Plasma therapy (convalescent) into infected patients may be of clinical benefit [232, 233] . Recently, the FDA has passed a few guidelines recommending medical professionals and researchers on the administration and study of investigational COVID-19 convalescent plasma [234] . Llama derived antibodies called VHH and bacterial super glue to form specific multimeric VHH with potential antiviral activity [235, 236] . This novel approach opens up new opportunities to optimize, reformate, and validate novel tools. Another promising treatment that may regenerate lung disease and reduce inflammation due to COVID-19 infection could be the use of stem cells. This very recent research approach is under trial while waiting for its validation [237] .

A major challenge in answering to emerging pandemic diseases is that vaccines may not extant or effectual against them. Each new strain requires a novel vaccine. It requires several months to years to J o u r n a l P r e -p r o o f design and mass-produce a safe and effective vaccine. Moreover, in emergency and severe illness difficulties may arise during transport and storage, vaccine security, maintenance of low temperature may become compromised. Besides, meeting supply-demand, distribution, and uptake of vaccines where vaccination is commonly not practiced are the significant challenges that the government may face during emerging pandemic diseases. Of note, many of the highlighted specifics in the review are in the developmental or experimental stage which requires clinical validation and some specifics may change with increasing data and more studies on COVID-19.

Synthetic DNA of SARS-CoV-2 have been cloned into yeast-based platform and reverse genetics maybe use to through light into the functional molecular biology and pathogenesis of emerging viruses including SARS-CoV-2 [238] . Genomic sequence was used for identifying novel drug targets against COVID-19 through viral-human protein interaction analysis and then cheminformatic analysis of existing compounds was carried resulting in the identification of 66 human proteins that can be drug gable [239] . The new SARS-CoV-2 outbreak has brought out many outstanding research work and studies. It includes understanding its infections, transmission, history, genome, and employment of previously reported drugs and many clinical trials with a single goal of designing a drug/vaccine to help our immune system fight better. Information regarding molecular function and structure of the viral proteins has helped greatly in the detection and evolution of new potent and efficient medicines. The rapid increase of information about SARS-CoV-2 along with highly sensitive and reproducible diagnostic and proper obeying of health authority's awareness and guidelines should bring about control of COVID-19 soon. Spike protein of 1300 amino acid with NTD, N terminal domain; RBD, receptor binding domain, RBM, receptor binding motif; SD1, subdomain 1; SD2, subdomain 2 are the components of S1 subunit, Left side (can be divided into S1A, S1B and S1C/D) and FP, fusion peptide; HR1, heptad repeat 1; HR2, hepted repeat 2; TM, transmembrane region; IC, intracellular domain are the components of S2 subunit, right side. C) Overview of proteolytic processing of SARS-CoV-2. Replicase polyprotein pp1ab (740-810 kDa) which gets processed into nonstructural proteins (nsps). The 3C-like protease (3CL-PRO, marked in red) in SARS-CoV-2, may be responsible for cleaving the C-terminus of replicase polyprotein. The polyproteins are processed by papain like protease (presented in red). RNA-dependent RNA polymerase (RdRp), responsible for viral genome replication and transcription is indicated in red color. 

Severe acute respiratory syndrome (SARS): epidemiology and clinical features

Global research trends of Middle East respiratory syndrome coronavirus: a bibliometric analysis

novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clinical and translational medicine

The SARS-CoV-2 Outbreak: What We Know

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Epidemiology and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Association between peripheral blood oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio time at risk and hospital mortality in mechanically ventilated patients

Novel coronavirus 2019-nCoV: Early estimation of epidemiological parameters and epidemic predictions. medRxiv

) WHO (World Health Organization)

Presymptomatic transmission of SARS-CoV-2 Singapore

Genome wide structure and functional modeling

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation

COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis

Structural basis for the inhibition of the papainlike protease of SARS-CoV-2 by small molecules

Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle

The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

A dynamic regulatory interface on SARS-CoV-2 RNA polymerase

Multiple enzymatic activities associated with severe acute respiratory syndrome virus helicase

Structural Basis for Helicase-Polymerase Coupling in the SARSCoV-2 Replication-Transcription Complex

The crystal structure of nsp10-nsp16 heterodimer from SARS-CoV-2 in complex with S-adenosylmethionine

Structural and biochemical characterization of endoribonuclease Nsp15 encoded by middle east respiratory syndrome coronavirus

Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2

Crystal structure of the SARS-CoV-2 nonstructural protein 9

Severe acute respiratory syndrome coronavirus nsp9 dimerization is essential for efficient viral growth

Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase

Evidence that TMPRSS2 activates the severe acute respiratory Syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells

An RNA stem-loop within the bovine coronavirus nsp1 coding region is a cis-acting element in defective interfering RNA replication

An optimal cis-replication stem-loop IV in the 5′ untranslated region of the mouse coronavirus genome extends 16 nucleotides into open reading frame 1

The solution structure of coronaviral stem-loop 2 (SL2) reveals a canoniacal CUYG tetraloop fold

Stem-loop III in the 5′ untranslated region is a cis-acting element in bovine coronavirus defective interfering RNA replication

Secondary structural elements within the 3′ untranslated region of mouse hepatitis virus strain JHM genomic RNA

A hypervariable region within the 3′ cis-acting element of the murine coronavirus genome is nonessential for RNA synthesis but affects pathogenesis

A phylogenetically conserved hairpin-type 3′ untranslated region pseudoknot functions in coronavirus RNA replication

A bulged stem-loop structure in the 3′ untranslated region of the genome of the coronavirus mouse hepatitis virus is essential for replication

Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step

Replication of coronavirus MHV-A59 in sac-cells: determination of the first site of budding of progeny virions

The production of recombinant infectious DI particles of a murine coronavirus in the absence of helper virus

Clinical and immunological features of severe and moderate coronavirus disease 2019

The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?

Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo

Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

HCA Lung Biological Network, SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

COVID-19: risk for cytokine targeting in chronic inflammatory disease?

Cross-species transmission of the newly identified coronavirus 2019-nCoV

Diagnostic molecular biology

et al Detection of 2019 novel coronavirus (2019-nCoV) by real time RT-PCR

Early diagnosis of SARS coronavirus infection by real-time RT-PCR

Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus

Reverse Transcriptase PCR diagnostic assay for the coronavirus associated with severe acute respiratory syndrome

Double-quencher probes improved the detection sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by one-step RT-PCR. medRxiv

SARS-CoV-2 detection from nasopharyngeal swab samples without RNA extraction

Evaluation of COVID-19 RT-Q PCR test in multi-sample pools

Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic

reconsidered: the meaning of these terms in analytical and diagnostic settings

Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19

False-Negative COVID-19 Testing: Considerations in Obstetrical Care

Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak

A Cautionary Tale of False-Negative Nasopharyngeal COVID-19 Testing

False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence

Comparative Performance of SARSCoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit

US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2

The interpretation of SARS-CoV-2 diagnostic tests

Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review

Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays

DNA detection using recombination proteins

Loop-mediated isothermal amplification of DNA

Rapid detection of SARS-CoV-2 using reverse transcription RT-LAMP method. medRxiv

Rapid colorimetric detection of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic plat-form: Ilaco.medRxiv

Helicase-dependent isothermal DNA amplification

Automatic detection of coronavirus disease (COVID-19) using X-ray images and deep convolutional neural networks

Chest CT findings in 2019 novel coronavirus(2019-nCoV) infections from Wuhan, China: key points for the radiologist. Radiol., 2020

et al Review of artificial intelligence techniques in imaging data acquisition, segmentation and diagnosis for COVID-19

et al CRISPR-Cas-12-based detection of SARS-CoV-2

Nucleic acid detection with CRISPR-Cas13a/C2c2. Science

SHERLOCK: Nucleic acid detection with CRISPR nuclease

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43

Advice on the use of point-of-care immunodiagnostic tests for COVID-19, WHO (World Health Organization

SARS-CoV-2 diagnostic pipeline, FIND

National Institute of Virology develops 1 st indigenous ELISA test kit for Covid-19: Harsh Vardhan

India's first paper-strip test for Covid-19, CSIR lab makes a breakthrough, 2020. 145. Performance evaluation of commercial kits for detection of SARS-CoV-2 RNA by Real Time PCR

Guidance on rapid antibody kits for COVID-19, ICMR, 2020

COVID-19 Vaccine Tracker

Coronavirus: A new type of vaccine using RNA could help defeat COVID-19. The Conversation

These 23 companies are working on coronavirus treatments or vaccines here are where things stand

First Clinical Trial for COVID-19 Treatment in United States Launched. Contagion Live

Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results in an open-label non-randomized clinical trial

Mechanism of action of hydroxychloroquine and chloroquine: implications for rheumatology

A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence

Remdesivir and chloroquine effectively inhibit the recent emerged novel coronavirus (2019-nCoV) in vitro

Treatment for severe acute respiratory distress syndrome from COVID-19

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

FDA approves remdesivir for treatment of COVID-19, EPR

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

Coronavirus disease 2019 (COVID-19) current status and future perspectives

A human monoclonal antibody blocking SARS-CoV-2 infection

Enlisting monoclonal antibodies in the fight against COVID-19, NIH's. Director's. Blog

Israel develops key Covid antibody that ‗attacks and neutralises' the virus in patient body. The Print

A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge, bioRxiv

The COVID-19 vaccine development landscape

China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data. Fierce Pharma

A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)‖, Clinical Trial Database

University of Oxford Commences Clinical Trial for Vaccine Candidate (ChAdOx1 nCoV-19) Targeting COVID-19

A Study of a Candidate COVID-19 Vaccine (COV001)

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates against COVID-19 in Healthy Adults

Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19)

IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection

Clinical trial number NCT04299724 for "Safety and Immunity of Covid-19 aAPC Vaccine

Clinical trial number NCT04276896 for "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Evaluating the Safety, Tolerability and Immun ogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19‖

Clinical trial number ChiCTR2000031809 for "A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated novel coronavirus pneumonia vaccine (vero cells)

Draft landscape of COVID-19 candidate vaccines, World Health Organization

COVID-19 vaccine tracker

COVID-19 medicago development program

CSIR receives approval for clinical trial of t wo drugs, ‗phytopharmaceutical & favipiravir' to treat COVID-19

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

World's First Clinical Trial of Homeopathic Medicine on COVID-19 has begun at Agra (India). COVID-19 Homeopathy Database

Bryona Elva-200 drug corona patient claims recovery in seven days

Cuba promotes homeopathy as effective ‗weapon' against the coronavirus, Miamiherald

Homeopathic clinical features of 18 patients in COVID-19 outbreaks in Hong Kong

Symptomatic COVID-19 positive and likely patients treated by homeopathic physicians -an Italian descriptive study, Scientific communication to medical colleagues

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

A randomized controlled trail assessing the efficacy of Lianhua Qingwen as an adjuvant treatment in patients with mild symptoms of COVID-19‖

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Traditional Chinese medicine for Covid-19 treatment

Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia protocol for a systematics review and meta-analysis

Ayurvedic treatment of COVID-19/ SARS-CoV-2: A case report

Traditional Chinese medicine treatment of COVID-19

COVID-19 cure search: India starts clinical trials of Ayush Medicines like Ashwagandha, Guduchi, Financial Express

Thailand clears use of herbal medicine for COVID-19 treatment

Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update

Clinical trial number NCT04323345 for "Efficacy of natural honey treatment with novel coronavirus‖

Clinical trial number NCT04347382 for "Honey and Nigella sativa trial against COVID-19 (HNS-COVID-PK)‖, Clinical Trial Database

Clinical trial number NCT04323332 for "Traditional Chinese Medicine for severe COVID-19‖

Potential role of Gum Arabic as immunomodulatory agent among COVID 19 patients (GA and COVID19)‖, Clinical Trial Database

A phase II, controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19‖

Effects of Nigella Sativa as a Treatment of Patients with Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study

10 COVID busting designs: spraying drones, fever helmets, and antivirus snoods, The guardian

500 membrane based face-masks made by CSMCRI were given for user trial and feedback to Indian Red Cross Society

DRDO develops WiFi-enabled UV disinfection tower

Mobile virology research lab and diagnostics laboratory (MMVRDL), DRDO. Accessed

Covid-19: DRDO comes with new technology to disintegrate coronavirus. Financial Express

IIT students develop incubation boxes for COVID-19 patients with breathing problems, Outlook The News Scroll

RNA-directed gene editing specifically eradicates latent and prevents new hiv-1 infection

Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing

CRISPR/Cas9 -derieved mutations both inhibit HIV-1 replication and accelerate viral escape

CRISPR/Cas9 gene editing technology and its application to the coronavirus disease (COVID-19), a review

Development of CRISPR as an antiviral strategy to combat SARS-C0V-2 and influenza

Programmable inhibition and detection of RNA viruses using Cas13

High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelian cell gene editing

Durable transgene expression in vivo using systemic, non-viral DNA delivery

Systems of delivery of CRISPR/Cas9 ribonucleoprotein complexes for genome editing

Nano-based approach to combat emerging viral (NIPAH virus) infection

Mode of antiviral action of silver nanoparticles against HIV-1

Gold nanoparticles as an HIV entry inhibitor

Detection of influenza virus using peroxidasemimic of gold nanoparticles

Can nanotechnology and materials science help the fight against SARS-CoV-2?

Ultrashort pulsed laser treatment inactivates viruses by inhibiting viral replication and transcription in the host nucleus

Oxygen-dependent laser inactivation of murine norovirus using visible light lasers

Lung ultrasound in the critically ill (LUCI): a translational discipline

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Llama-derieved single domain antibodies to build multivalent, superpotent and boardened neutralizing anti-viral molecules

Multimeric single-domain antibody complexes protect against bunyavirus infections, eLife, 2020

Can stem cells beat COVID-19: advancing stem cells and extracellular vescicles towards mainstream medicine for lung injuries associated with SARS-CoV-2 infections

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform

A SARS-CoV-2-Human protein-protein interaction map reveals drug targets and potential drug repurposing

Basic structure of SARS-CoV-2 and genome arrangement

Structure and functions of proteins involved in genome expression. 3. Updates on COVID-19 therapeutics and preventive methods